Descovy vs Taficita: Is the Generic TAF/FTC Identical for PrEP?

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Tenofovir alafenamide is Gilead’s second-generation prodrug of tenofovir, designed to address two limitations of the original tenofovir disoproxil fumarate (TDF) in Truvada: chronic bone density reduction and progressive renal function decline. TAF achieves the same intracellular tenofovir-diphosphate concentrations as TDF (the active antiviral metabolite that blocks HIV reverse transcription) while producing approximately 90% lower plasma tenofovir levels — reducing systemic exposure to the molecule responsible for the bone and renal signals.

Descovy received FDA approval in April 2015 for HIV-1 treatment in combination regimens, and an indication expansion to HIV pre-exposure prophylaxis (PrEP) was approved in October 2019. The DISCOVER trial (Mayer et al., Lancet, 2020¹) randomised 5,387 men who have sex with men and transgender women to TAF/FTC vs TDF/FTC for PrEP — demonstrating non-inferiority of TAF/FTC in HIV-1 prevention with improved bone and renal markers.

Cipla Ltd’s Taficita is among the most widely distributed WHO-GMP generic TAF/FTC products globally, manufactured at the same Mumbai facility producing Tenvir-EM (the generic TDF/FTC equivalent of Truvada). Our companion piece Truvada vs Tenvir-EM covers the older-generation TDF/FTC supply chain in detail.

TL;DR comparison table

How TAF differs from TDF (and why it matters)

Tenofovir is the active antiviral nucleotide that blocks HIV reverse transcription — the molecule does the antiviral work inside CD4+ T-cells. Both TDF and TAF are prodrugs designed to deliver tenofovir into cells; they differ in pharmacokinetics:

• TDF (tenofovir disoproxil fumarate): hydrolysed in plasma to tenofovir, producing relatively high circulating tenofovir levels. Tenofovir is taken up into target cells and phosphorylated to tenofovir-diphosphate.
• TAF (tenofovir alafenamide): stable in plasma, hydrolysed inside target cells by cathepsin A to tenofovir, then phosphorylated to tenofovir-diphosphate. Produces approximately 90% lower plasma tenofovir while achieving equivalent (or slightly higher) intracellular tenofovir-diphosphate.

The clinical consequence: the bone density reduction and renal function decline associated with chronic TDF use are signals from systemic tenofovir exposure, not from intracellular tenofovir-diphosphate (which is the active antiviral). TAF, by minimising systemic exposure while preserving intracellular concentrations, reduces those side effects.

This is the principal reason a clinician would choose Descovy/Taficita over Truvada/Tenvir-EM: patients with osteopenia, osteoporosis, fragility-fracture history, age >50, or pre-existing renal impairment benefit from the TAF prodrug. For other patients, the modest lipid penalty of TAF (mildly elevated LDL cholesterol) is a counterbalancing consideration.

The DISCOVER trial: where TAF/FTC was validated for PrEP

The DISCOVER trial¹ was a 96-week randomised double-blind trial comparing TAF/FTC vs TDF/FTC for HIV-1 PrEP in 5,387 men who have sex with men and transgender women. Results:

• HIV-1 acquisition: 7 cases TAF/FTC vs 15 cases TDF/FTC. Non-inferior to TDF/FTC for HIV-1 prevention.
• Bone mineral density: TAF/FTC arm showed +0.5% mean change over 96 weeks; TDF/FTC showed −1.0%. Statistically and clinically meaningful.
• Renal function (eGFR): TAF/FTC arm showed +1.8 mL/min/1.73m² mean change; TDF/FTC showed −2.3.
• Lipids: TAF/FTC arm showed modest increases in LDL cholesterol (+15 mg/dL); TDF/FTC showed neutral change.

The trial established TAF/FTC PrEP for MSM and transgender women. It explicitly did not include cisgender women, so the FDA indication is limited to MSM/TGW. For receptive vaginal sex PrEP, TDF/FTC (Truvada or Tenvir-EM) remains the FDA-approved choice; this is a meaningful clinical point.

Bioequivalence

Generic TAF/FTC entered global markets earlier than US retail (US Descovy patents extend further). Cipla’s Taficita is WHO-Prequalified and applies the same Cmax/AUC bioequivalence criterion as the FDA. The molecule and formulation are pharmaceutically identical to Descovy.

Side effects: identical molecule, identical profile

Descovy/Taficita’s side-effect profile applies across all supply chains and is generally milder than TDF/FTC for the bone/renal signals:¹

• Mild GI side effects in first 4 weeks — nausea, diarrhoea (lower rates than TDF/FTC)
• Mild headache (~5–7%)
• Bone mineral density: no meaningful change in 96-week DISCOVER (vs ~1% loss on TDF/FTC)
• Renal function: no meaningful eGFR decline (vs modest decline on TDF/FTC)
• Lipid changes: modest LDL cholesterol increase (~10–15 mg/dL) — TAF’s principal disadvantage vs TDF
• Weight gain: modest increase relative to TDF (which is weight-neutral or slightly weight-favourable)

Contraindications and monitoring

Manufacturer disclosure: who makes Taficita?

Taficita is manufactured by Cipla Ltd, headquartered in Mumbai — the same WHO-GMP-certified facility producing Tenvir-EM and decades of generic antiretrovirals for global HIV programs. Cipla holds approvals from US FDA, UK MHRA, WHO Prequalification, and most national regulatory bodies. Cipla supplied generic ARVs to PEPFAR, the Global Fund, and national procurement programs in dozens of countries through the 2000s and 2010s. Per-batch finished-product release for Taficita includes HPLC content uniformity for both active ingredients, dissolution testing per USP, and stability monitoring per ICH. Certificates of Analysis are available on request through MedsBase customer support.

How to order Taficita from MedsBase

Taficita ships worldwide from MedsBase in discreet packaging. Payment via crypto (USDT, BTC, ETH via Plisio), credit card via a regulated crypto on-ramp (statement descriptor is the on-ramp provider name — a regulated card-payment processor — never MedsBase), or SEPA where available. See our credit card payment guide. Orders are covered by the MedsBase Reshipment Assurance Policy. Browse the Taficita product page.

Descovy/Taficita vs Truvada/Tenvir-EM: which to choose?

The choice between TDF/FTC and TAF/FTC for PrEP is increasingly individualised. Decision factors:

• Favours TAF (Descovy/Taficita): osteopenia, osteoporosis, fragility fracture history, age >50, pre-existing eGFR 30–60, MSM/TGW use case.
• Favours TDF (Truvada/Tenvir-EM): elevated cardiovascular risk or dyslipidaemia (TDF is lipid-favourable), event-driven 2-1-1 PrEP dosing (validated only for TDF), receptive vaginal sex (TAF/FTC not FDA-approved for this indication), cost-conscious users where pricing matters even within the generic supply chain.
• Tie: daily oral PrEP for MSM/TGW with normal baseline bone/renal status and unremarkable lipid profile — either is reasonable. TDF is more extensively studied and cheaper; TAF has a slight bone/renal-safety edge.

Cipla and other WHO-GMP generic manufacturers produce both TDF/FTC (Tenvir-EM) and TAF/FTC (Taficita), enabling individualised choice without the branded supply chain’s cost differential. See our Truvada vs Tenvir-EM comparison for the TDF-specific supply chain details.

Pricing context: The brand-vs-generic price comparison on this page is one entry in MedsBase’s broader Brand-vs-Generic Medication Pricing Index — a quarterly-updated reference covering 15 brand-vs-generic pairs across ED, GLP-1, hair-loss, PrEP, and cosmetic clusters, with full methodology and citation disclosure.

Frequently Asked Questions

Is Taficita literally the same drug as Descovy?

Yes. Both contain tenofovir alafenamide 25 mg + emtricitabine 200 mg in a single oral tablet. The mechanism, dosing, half-life, efficacy, and side-effect profile are pharmacologically identical. The differences are the manufacturer, the inactive excipients, and the price.

Is Taficita FDA-approved?

Taficita is not registered with the US FDA. However, Cipla manufactures Taficita under WHO Prequalification — the same program that has supplied generic TDF/FTC and other ARVs to global HIV programs for two decades. WHO PQ applies the same bioequivalence and quality-control standards used by the FDA. Generic TAF/FTC has not yet entered US retail pharmacies because Gilead patents on TAF extend further than TDF, but Taficita is widely used in national HIV programs globally.

Should I switch from Truvada/Tenvir-EM to Descovy/Taficita?

For most users without specific bone or renal concerns, switching is not clinically necessary. TDF/FTC is more extensively studied for PrEP, supports the event-driven 2-1-1 regimen, has cisgender female efficacy data, and is cheaper even within the generic supply chain. The switch makes most sense for users with osteopenia, osteoporosis, fragility fracture history, pre-existing renal impairment, or age >50.

Can I use Taficita for receptive vaginal sex PrEP?

This is the one place TAF/FTC differs meaningfully from TDF/FTC in PrEP indication. The DISCOVER trial that validated TAF/FTC PrEP did not include cisgender women, so the FDA indication is limited to MSM and transgender women. For receptive vaginal sex PrEP, TDF/FTC (Truvada or Tenvir-EM) is the FDA-approved choice with efficacy data from the Partners PrEP trial.

Is the event-driven 2-1-1 PrEP dose validated for Taficita?

No. The IPERGAY trial that validated 2-1-1 event-driven dosing used TDF/FTC (Truvada). The pharmacokinetic profile of TAF (low plasma tenofovir, high intracellular tenofovir-diphosphate) is different enough that 2-1-1 effectiveness cannot be assumed from the TDF data. Use daily dosing for Taficita/Descovy.

What about the lipid signal with TAF?

TAF/FTC modestly increases LDL cholesterol (~10–15 mg/dL on average) versus TDF/FTC’s neutral lipid effect. For users with established dyslipidaemia or elevated cardiovascular risk, this is a meaningful consideration. For users without lipid concerns, the bone and renal-safety benefits of TAF generally outweigh the lipid penalty.

Will my bones be okay long-term on Taficita?

The DISCOVER trial showed no meaningful bone density change over 96 weeks on TAF/FTC PrEP, versus approximately 1% loss on TDF/FTC. For chronic PrEP use lasting years or decades, the bone benefit of TAF accumulates. This is the principal long-term reason to prefer TAF over TDF.

How is Taficita so much cheaper than Descovy?

Gilead Descovy’s pricing reflects R&D recovery, the DISCOVER and other pivotal trials, US distribution and sales infrastructure, DTC advertising, and PBM rebate absorption. Cipla has been producing generic ARVs (including TAF/FTC) for global HIV programs at scale for years; the manufacturing economics are well established. The Taficita price reflects only the manufacturing and distribution cost without the branded-drug overhead.

Sources

1. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER). Lancet. 2020;396(10246):239–254.
2. US Food and Drug Administration. NDA 208215, Descovy (emtricitabine/tenofovir alafenamide). Approval letter, 4 April 2015 (treatment); supplemental approval 3 October 2019 (PrEP).
3. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.
4. Cipla Ltd. WHO Prequalification under the WHO PQ program; multi-decade ARV supplier to PEPFAR and the Global Fund.

Last clinically reviewed: 18 May 2026.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.